Advanced Stage Relapsed Refractory Cancer clinical trials

Explore recruiting advanced stage relapsed refractory cancer clinical trials.

Recruiting advanced stage relapsed refractory cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Stage Relapsed Refractory Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability, and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer (EVICTION Study)

Belgium, France, Spain, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Advanced Stage Relapsed Refractory Cancer trials by city

Advanced Stage Relapsed Refractory Cancer clinical trials

Recruiting advanced stage relapsed refractory cancer studies right now

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

A Study of PHST001 in Advanced Solid Tumors

A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors

Evaluate the Safety and Clinical Activity of HH2853

Also recruiting in Europe

A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability, and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer (EVICTION Study)

Advanced Stage Relapsed Refractory Cancer trials by city

Other conditions